Evidence map›Paper›PMID 29119253›Full record

ArticleMedical microbiology and immunology2018

Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.

Anna Mania, Mariusz Kaczmarek, Paweł Kemnitz, Katarzyna Mazur-Melewska, Magdalena Figlerowicz, Jan Sikora, Wojciech Służewski, Jan Żeromski

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical microbiology and immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anna ManiaDepartment of Infectious Diseases and Child Neurology, University of Medical Sciences Poznan, Szpitalna 27/33, 60-572, Poznan, Poland. mania@mp.pl.ORCID http://orcid.org/0000-0003-0141-2560
Mariusz KaczmarekChair of Clinical Immunology, University of Medical Sciences Poznan, Poznan, Poland.
Paweł KemnitzDepartment of Infectious Diseases and Child Neurology, University of Medical Sciences Poznan, Szpitalna 27/33, 60-572, Poznan, Poland.
Katarzyna Mazur-MelewskaDepartment of Infectious Diseases and Child Neurology, University of Medical Sciences Poznan, Szpitalna 27/33, 60-572, Poznan, Poland.
Magdalena FiglerowiczDepartment of Infectious Diseases and Child Neurology, University of Medical Sciences Poznan, Szpitalna 27/33, 60-572, Poznan, Poland.
Jan SikoraChair of Clinical Immunology, University of Medical Sciences Poznan, Poznan, Poland.
Wojciech SłużewskiDepartment of Infectious Diseases and Child Neurology, University of Medical Sciences Poznan, Szpitalna 27/33, 60-572, Poznan, Poland.
Jan ŻeromskiChair of Clinical Immunology, University of Medical Sciences Poznan, Poznan, Poland.
Poznan University of Medical Sciences · PL

Funding

Narodowe Centrum Nauki NN 407 012 036
6 · The paper itself

Abstract

Treatment with pegylated interferon-α and ribavirin (PEG-IFN/RBV) is the only choice for chronic hepatitis C (CHC) in children. Natural killer (NK) cells were described to play a vital role in CHC. The aim of this study was to analyze the expression of peripheral blood NK cell receptors in their relation to PEG-IFN/RBV treatment response. Study included 26 children with CHC-13 boys, age range 13.42 ± 3.28 years. Blood for biochemical, virological and cytometric testing was taken for evaluation prior to the antiviral treatment. NK cell receptors were detected by flow cytometry and the results were presented as proportion of cells and mean fluorescence intensity (MFI). Therapy consisted of PEG-IFNα-2b (60 μg/m

Indexed as

AdolescentAge FactorsAntiviral AgentsChildChild, PreschoolFemaleHepatitis C, ChronicHumansInfantInterferon-alphaInterferon alpha-2MalePolyethylene GlycolsPrognosisReceptors, KIR2DL3Receptors, KIR3DL1Antiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsReceptors, KIR2DL3Receptors, KIR3DL1Recombinant ProteinsRibavirinAntiviral treatmentChildrenChronic hepatitis CNK cell receptorsPegylated interferon-alpha

Identifiers

PMID29119253
PMCPMC5780529
OpenAlexW2767794578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.